Search

Displaying results 3801 - 3810 of 7897 in total
  1. Drug

    Veligrotug

    go.drugbank.com/drugs/DB18976
    Approved

    Veligrotug is a humanized IgG1 monoclonal antibody that binds the insulin-like growth factor-1 receptor and blocks ligand-induced receptor autophosphorylation, interrupting IGF-1R signaling. … [L63798] Thyroid eye disease has historically been managed differently depending on whether it is caught in the active inflammatory phase or has become chronic - Viridian describes veligrotug-vvze as the

  2. Drug

    LP-2307

    go.drugbank.com/drugs/DB17470
    Experimental

    LP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.

  3. Drug

    SMART101

    go.drugbank.com/drugs/DB18370
    Investigational

    SMART101 is an investigational cell therapy comprising human allogeneic CD34-CD7+ T cell progenitors that were cultured ex vivo.

  4. Drug

    X-376

    go.drugbank.com/drugs/DB13104
    Investigational

    X-376 is an inhibitor of the anaplastic lymphoma kinase (ALK) which can penetrate the blood brain barrier.[A265085]

  5. Drug

    ALLO-605

    go.drugbank.com/drugs/DB18641
    Investigational

    ALLO-605 is an allogeneic turbo chimeric antigen receptor (Turbocar) T Cell therapy targeting B Cell maturation antigen (BCMA).

  6. Drug

    RC88

    go.drugbank.com/drugs/DB18697
    Experimental

    RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).

  7. Drug

    Povetacicept

    go.drugbank.com/drugs/DB18996
    Investigational

    Povetacicept is under investigation in clinical trial NCT05757570 (An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias).

  8. Drug

    Ovatodiolide

    go.drugbank.com/drugs/DB19264
    Investigational

    Ovatodiolide is under investigation in clinical trial NCT04220411 (A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD)).

  9. Drug

    R112

    go.drugbank.com/drugs/DB06252
    Experimental

    R112 is an investigational compound developed to treat Allergic Rhinitis. It's mechanism of action is to inhibit SYK kinase.

  10. Drug

    Elacridar

    go.drugbank.com/drugs/DB04881
    Investigational

    In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline. … Elacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors.